• 1
    Bruner DW, Bryan CJ, Aaronson N et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007; 25: 50517
  • 2
    Wagner LI, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol 2007; 25: 505862
  • 3
    Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007; 109: 223947
  • 4
    Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 73543
  • 5
    Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007; 177: 21516
  • 6
    Goldner G, Wachter-Gerstner N, Wachter S, Dieckmann K, Janda M, Potter R. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 2003; 179: 3207
  • 7
    Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997; 6: 22536
  • 8
    Clauser SB, Ganz PA, Lipscomb J, Reeve BB. Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. J Clin Oncol 2007; 25: 504950
  • 9
    Sanghani MV, Ching J, Schultz D et al. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol 2004; 22: 1658
  • 10
    D'Amico AV, Manola J, McMahon E et al. A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization. Urology 2006; 67: 7804
  • 11
    Court LE, D'Amico AV, Kadam D, Cormack R. Motion and shape change when using an endorectal balloon during prostate radiation therapy. Radiother Oncol 2006; 81: 1849
  • 12
    Woel R, Beard C, Chen MH et al. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 2005; 62: 3926
  • 13
    Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001; 39: 111830
  • 14
    Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care 2003; 41: 92336
  • 15
    Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol 2006; 176: 155863; discussion 1563–4
  • 16
    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 1322
  • 17
    Neter J, Wassermann W, Kutner M. Simultaneous inferences and other topics in regression analyses-1, in Applied Linear Regression Models, Homewood, IL: Irwin Professional Publishing, 1983: 1503
  • 18
    Liu L, Glicksman AS, Coachman N, Kuten A. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 6571
  • 19
    Matzinger O, Duclos F, van den Bergh A et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009; 45: 282534
  • 20
    De Meerleer G, Vakaet L, Meersschout S et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 2004; 60: 77787
  • 21
    Guerrero Urbano T, Khoo V, Staffurth J et al. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 2010; 22: 23644
  • 22
    Bastasch MD, Teh BS, Mai WY, McGary JE, Grant WH 3rd, Butler EB. Tolerance of endorectal balloon in 396 patients treated with intensity-modulated radiation therapy (IMRT) for prostate cancer. Am J Clin Oncol 2006; 29: 811
  • 23
    Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27: 391622
  • 24
    Geinitz H, Thamm R, Scholz C et al. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer. Strahlenther Onkol 2010; 186: 4652
  • 25
    Pinkawa M, Holy R, Piroth MD et al. Consequential late effects after radiotherapy for prostate cancer – a prospective longitudinal quality of life study. Radiat Oncol 2010; 5: 27